Zolpidem tartrate.txt

CLINICAL USE

Insomnia (short-term treatment)

DOSE IN NORMAL RENAL FUNCTION

5–10 mg at night

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 764.9

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 92.5

%Excreted unchanged in urine &nbsp &nbsp : Negligible (56% as active metabolites)

Volume of distribution (L/kg) &nbsp &nbsp &nbsp : 0.34–0.54 (depends on age)

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp : Average: 2.4/ Increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Not dialysed. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Not dialysed. Dose as in normal renal function

HDF/high flux &nbsp : Unknown dialysability. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp: Not dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antibacterials: metabolism accelerated by rifampicin

Antipsychotics: enhanced sedative effects

Antivirals: concentration increased by ritonavir (risk of extreme sedation and respiratory depression) – avoid concomitant use

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

First pass metabolism by liver is 35% Clearance is reduced in renal impairment .

Tags: post-by-auto-php